Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model
Retrieved on:
Thursday, March 18, 2021
The study evaluated the efficacy of topically applied CF602 in a 4-cohort study with diabetic Sprague-Dawley (SD) rats receiving placebo; 100nM CF602; 500nM CF602.
Key Points:
- The study evaluated the efficacy of topically applied CF602 in a 4-cohort study with diabetic Sprague-Dawley (SD) rats receiving placebo; 100nM CF602; 500nM CF602.
- Treatment with CF602 at a dose of 500 nM resulted in statistically significant improvement of erectile dysfunction compared to vehicle treated controls when measured in a two-way ANOVA followed by Bonferroni multiple comparisons post-hoc analysis (p
- As a topical formulation, CF602 may offer distinct safety and efficacy advantages over oral ED drugs on the market today, stated Can-Fite CEO Dr. Pnina Fishman.
- CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction.